Business Wire

VERACODE

28.7.2022 08:52:11 CEST | Business Wire | Press release

Share
Veracode Expands Platform Capabilities in its EU-Resident Platform

Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform in Europe. Companies can now secure their software across the entire software development lifecycle (SDLC) with the added capabilities of dynamic analysis and API scanning, complementing Veracode’s static analysis, software composition analysis and manual penetration testing tools. The Veracode European Region , a cloud-based instance, allows customer data to stay resident in the EU to meet policy requirements for cloud computing.

Demand for a SaaS-based software security solution that supports data residency has never been greater. With a 20x increase * in security scanning cadence over the past decade, organisations are now testing apps for flaws more thoroughly than ever. Many are shifting further left and combining static, dynamic, and software composition analysis to gain a comprehensive view of risk and compliance to policies.

Veracode’s EMEA Chief Technology Officer, John Smith, said, “The European market has a growing need to consolidate and automate application security, while meeting stringent data residency requirements. The options for achieving this at scale are limited and complex: on-premise solutions require a large, upfront investment and frequent upgrades, while other SaaS platforms are often a pared-down version of existing on-premise products. Veracode’s cloud-native platform helps customers keep costs down and increase efficiencies by integrating multiple software security tools into one easy-to-use solution that also monitors policy compliance.”

Based in Frankfurt, Germany, the Veracode European Region is a cloud-based instance that offers customers in EMEA a broad suite of solutions as part of its unified Continuous Software Security Platform, which bridges the gap between security and development teams. Dynamic analysis and API scanning are the latest capabilities to be made available in the market. The integrated platform is unique since it gives customers a “single pane of glass” view of security posture across their entire SDLC.

Seamlessly embedded into the environments where developers work, Veracode creates a frictionless experience for developers to code securely without compromising speed of delivery. This is paramount to help businesses keep pace with accelerating deployment times, as well as to provide a comprehensive view of risk, remediation guidance, peer benchmarking, and rich analytics throughout the development pipeline.

Powered by nearly two decades of aggregate data, the cloud-native platform continually finetunes itself to improve accuracy, yielding impressively low false-positive rates. It also streamlines workflows by running daily updates of the vulnerability database, so customers are immediately apprised of any potential threats.

A customer of Veracode, a European commerce body, said, “The privacy and protection of our customers is our highest priority, so we need to be confident in our software security programme. Veracode gives us this assurance with a fully SaaS platform that is resident in the EU. Initially, we needed an automated dynamic analysis product that could crawl our applications at scale but wanted to avoid the pain of amassing several disparate tools over time. With Veracode, we are safe in the knowledge that we can leverage multiple solutions in one place as we continue to shift security further left.”

Find out more about Veracode’s European Region here .

*Veracode State of Software Security Report v12, February 2022

About Veracode

Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.

Learn more at www.veracode.com , on the Veracode blog and on Twitter .

Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/VeracodeInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye